Wilmington PharmaTech (“Wilmington”), a leading U.S.-based research, development, and manufacturing organization (CRDMO) ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API ...

Arul Ramadurai, CCO, Axplora, discusses the company’s investment in expanding its HPAPI development and manufacturing ...

TEDA TIANJIN, China--(BUSINESS WIRE)-- Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot ...

Teva announced its intention to divest its active-pharmaceutical ingredient business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees ...

Teva (NYSE:TEVA) plans to divest its active-pharmaceutical ingredient (API) business as part of its Pivot to Growth strategy to focus on its core business strengths. "The intent to divest TAPI will ...

Raubling, Germany-based Axplora, which focuses on small-molecule API manufacturing reports that its total investments initiated across its global network in 2025 will exceed €100 million ($115.6 ...

Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development and manufacturing organization (CRDMO) focused on complex custom small molecule API, today announced that it has ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

MITOLINE ™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030 ...

qualified companies can utilize one or more of three established pharmaceutical manufacturing plants on the campus under a ...